A Randomised Double Blind Placebo-Controlled, Long-Term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis.

Trial Profile

A Randomised Double Blind Placebo-Controlled, Long-Term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2012

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jul 2012 This trial is recruiting in France and has been completed in Belgium, discontinued in Netherlands, Germany, United Kingdom.
    • 01 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 May 2010 Actual patient number (374) added, additional locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top